AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca datroway (datopotamab deruxtecan — direct product sales) — US YoY (%) (%)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
0.0%
Period ended Jun 30, 2026
Change on a year earlier
–
History
3 quarters
Since Q4 2025
Sources
3
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Datroway (datopotamab deruxtecan — direct product sales) — US YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0.0% | – | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 0.0% | – | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 0.0% | – | Form 6-K FY2025Q4 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Datroway (datopotamab deruxtecan — direct product sales) — US YoY (%) (%), quarterly Q4 2025–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_datroway_us_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.